Table 2 Standardized mortality ratios (SMR) of patients with MM, HL, DLBCL, and HL at diagnosis, and at 36-month landmark (SMR-36)

From: Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies

 

Diagnosis

36-month landmark

N

SMR (95% CI)

N

SMR-36 (95% CI)

MM

212

19.5 (15.2–24.5)

143

20.7 (14.7–28.3)

FL

168

4.2 (2.3–7.2)

114

3.8 (1.5–7.8)

DLBCL

193

13.0 (9.2–18.4)

110

3.1 (0.8–8.0)

HL

232

5.2 (2.6–9.3)

140

0.9 (0.0–5.1)

  1. MM multiple myeloma, FL follicular lymphoma, DLBCL diffuse large B-cell lymphoma, HL Hodgkin lymphoma
Back to article page